A phase IIa study of Tisotumab Vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer : updated safety and efficacy

Concin, N; Vergote, I; Dean, E; Lassen, U; Drew, Y; Machiels, J-P; Nielsen, D; Arkenau, T; Forster, M; Jones, R; Slomovitz, B; Spicer, J; Johnsson, M; Cornez, N; GENNIGENS, Christine; Fulton, B; Rangwala, R; Coleman, R; Hong, D

Poster (Scientific congresses and symposiums)

Concin, N; Vergote, I; Dean, E et al.

2017 • ESGO European Gynaecological Oncology Congress 2017

Permalink
https://hdl.handle.net/2268/220955

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

A phase IIA study of Tisotumab ... poster ESGO - CG.pdf

Publisher postprint (512.27 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

oncology; metastatic cervical cancer; Tisotumab

Disciplines :

Oncology

Author, co-author :

Concin, N

Vergote, I

Dean, E

Lassen, U

Drew, Y

Machiels, J-P

Nielsen, D

Arkenau, T

Forster, M

Jones, R

More authors (9 more)

Language :

English

Title :

A phase IIa study of Tisotumab Vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer : updated safety and efficacy

Publication date :

November 2017

Event name :

ESGO European Gynaecological Oncology Congress 2017

Event place :

Vienna, Austria

Event date :

2017 November 4-7

By request :

Yes

Audience :

International

Available on ORBi :

since 02 March 2018

Statistics

Number of views

161 (6 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics